July 2024—Diasorin received FDA 510(k) clearance for its NxTag Respiratory Pathogen Panel v2. The updated panel adds SARS-CoV-2 to its mix of 19 viral and two bacterial targets. The updated kit provides enhanced target performance to increase inclusivity and specificity, while improving usability of the product with easier-to-identify plate seals, according to a company press statement. The panel runs on the Magpix system, which tests up to 96 specimens in a single run.
Diasorin, 562-240-6500
